Gut Dysbiosis and Heart Failure: What IPA Evidence Shows

Heart failure and gut dysbiosis travel together often enough that the association now looks reproducible, not incidental. A 2025 meta-analysis of 25 studies involving about 3,200 patients found lower gut microbial diversity in people with heart failure than in healthy controls: standardized mean difference −0.55 (95% confidence interval −0.75 to −0.35; p<0.001). The same review found distinct overall microbial-community patterns between groups (p<0.001). Albulushi et al. pooled studies from different regions, diets, heart-failure causes, and sequencing methods. The signal survived that messiness.

The next question is harder: does an altered microbiome help drive heart failure, or does heart failure alter the microbiome? Reduced cardiac output, intestinal congestion, inflammation, medication use, diet changes, and coexisting disease could all reshape gut ecology. Current human evidence cannot establish the direction of causation.

That distinction matters when a new metabolite enters the story. Indole-3-propionic acid, or IPA, has drawn attention because laboratory experiments suggest it can directly alter energy production in heart cells. It has a plausible mechanism. It does not yet have human heart-failure evidence.

Dysbiosis is a heart-failure phenotype, not a diagnosis

Microbial diversity is a broad measure of how many kinds of organisms are present and how evenly distributed they are. Lower diversity does not identify one guilty bacterium or prescribe one supplement. It says that, on average, the gut ecosystems of people with heart failure differ from those of healthy controls.

The pooled diversity result is statistically significant and reasonably precise, but it does not erase differences among the underlying studies. The included research used different 16S rRNA sequencing regions and primers, enrolled patients with different heart-failure causes and comorbidities, and came from populations with different dietary backgrounds. Random-effects modeling accounts for variation statistically; it cannot make nonidentical studies identical.

An earlier systematic review by Simadibrata et al. reached a compatible conclusion at the taxonomic level: heart-failure cohorts often showed depletion of bacteria that produce short-chain fatty acids and enrichment of potentially pathogenic species. Species-level findings varied with sequencing methods, so the reliable finding is the broader dysbiosis pattern rather than a universal microbial hit list.

TMAO remains the metabolite with human footing

Trimethylamine N-oxide, or TMAO, is the better-developed gut-metabolite story in heart failure. Gut microbes convert dietary choline, carnitine, and betaine into trimethylamine, which the liver converts to TMAO. A 2022 systematic review by Anderson et al. reported that TMAO is elevated in heart-failure plasma, tracks with disease severity, and has a microbiome-dependent biosynthetic pathway.

This does not prove that lowering TMAO prevents heart failure or improves survival. It does put TMAO ahead of newer candidates on the evidence ladder: researchers have measured it in human heart-failure cohorts and related it to clinical severity. The gut-heart literature also examines short-chain fatty acids and bile-acid signaling, which may be relevant to intestinal barrier function, inflammation, and metabolism. None has yielded a single, settled causal pathway.

For someone making dietary choices, that hierarchy argues against metabolite obsession. A dietary pattern that moderates red meat and eggs, major sources of carnitine and choline, addresses a pathway with human measurements. It should sit within ordinary cardiovascular care, not replace guideline-directed treatment, prescribed medication, or clinician advice.

IPA has a specific mitochondrial signal—and a large translational gap

IPA is a microbial breakdown product of tryptophan. In a reported screen of 25 gut-derived metabolites in HL-1 murine cardiomyocytes, IPA produced a biphasic response in mitochondrial respiration. Acute exposure increased oxygen-consumption rate by about 21.5%; 24-hour exposure at 1 to 100 micromolar reduced it by about 18.9%. Additional testing implicated inhibition within the electron-transport chain, and an isolated perfused mouse-heart model provided partial validation.

Those findings make IPA scientifically interesting, but they do not show that IPA harms human hearts. HL-1 cells are transformed murine cells, not adult human cardiomyocytes. Their metabolism does not fully reproduce human cardiac bioenergetics. The experiment also does not establish which IPA concentration occurs in people with heart failure, nor where the shift from an acute increase in respiration to chronic suppression occurs. Healthy-human serum reference values have been described around 1 to 5 micromolar, but that does not establish concentrations in heart failure or identify a therapeutic target.

The preclinical evidence also points in two directions. A separate 2024 animal study reportedly found that IPA improved diastolic dysfunction in an HFpEF model. That conflicts with the harmful signal reported in an HFrEF-context cell experiment. Different heart-failure phenotypes, model systems, exposure patterns, concentrations, and endpoints could explain the discrepancy. Until experiments test those possibilities directly, averaging the two results into a single IPA verdict would be fiction with better formatting.

IPA is a hypothesis with a measurable laboratory phenotype, not a validated heart-failure biomarker or treatment target.

No available human heart-failure cohort has established whether circulating IPA differs from controls, correlates with severity, predicts outcomes, or responds to a treatment alongside cardiac outcomes. Those are the basic studies needed before IPA belongs in a clinical recommendation.

Probiotics support the broader axis, not the IPA claim

Intervention trials offer a limited but useful test of whether changing the gut environment can affect cardiovascular markers. A 2026 systematic review and meta-analysis by Zhu et al. found statistically significant improvements in cardiac and inflammatory biomarkers across probiotic randomized controlled trials in heart failure. The review also emphasized heterogeneity in endpoints, which limits conclusions about outcomes such as mortality, ventricular function, or natriuretic peptides.

A 2023 meta-analysis by Taslim et al. similarly found reductions in C-reactive protein, malondialdehyde, and related cardiac-remodeling markers across randomized probiotic trials involving post-myocardial-infarction and heart-failure populations. Different probiotic species, doses, and treatment durations make it impossible to assign those changes to one organism or metabolite.

The closest individual clinical trial here was a single-center, double-blind study by Moludi et al. in 136 post-myocardial-infarction patients with heart-failure relevance. It reported effects on left-ventricular ejection fraction and remodeling markers after probiotic supplementation. Its design is stronger than an observational comparison, but its single-center setting limits generalizability. Neither this trial nor the meta-analyses measured IPA or selected probiotic strains to increase IPA-producing bacteria.

Inflammation may connect intestinal dysfunction and cardiac injury, but the mechanism remains unsettled. A 2026 review of NLRP3 inflammasome biology describes mitochondrial disruption, cell death, and inflammatory injury in sepsis-induced cardiomyopathy. Sepsis-induced cardiomyopathy is not chronic heart failure. It offers biological context, not direct proof that NLRP3 explains dysbiosis in chronic heart failure.

What to do with the evidence now

The practical conclusion is deliberately unglamorous. Heart failure is consistently associated with lower gut microbial diversity, and diet quality, fiber-rich foods, fermented foods, and carefully selected probiotics may support the broader gut-heart axis. The probiotic trials show biomarker and remodeling signals, not proof of fewer hospitalizations or longer life.

TMAO is the gut-derived metabolite with the clearest human heart-failure evidence. IPA deserves further study because its mitochondrial effects are specific and testable, but no human data establish that raising, lowering, or supplementing IPA improves heart failure. Do not build an IPA supplement strategy around cell-line results that conflict with an animal model. The next useful studies need human metabolomics, repeated measurements, defined heart-failure phenotypes, and clinical endpoints—not another confident label on an uncertain molecule.